Post Profile

How a Beleaguered Industry Needs to Adapt - and Why it Doesn't Have a Choice

The pharmaceutical industry has had a rough go of it lately. Between negative headlines (with the recent Mylan EpiPen controversy only the latest controversy), congressional inquiries and calls from insurers and the medical community to defend the price of medications, today's value-focused healthcare landscape presents an unprecedented set of challenges for the sector. This new level of pressure is exemplified by legislation currently under consideration in more than 10 states - including California, New York and Massachusetts - that would require drug manufacturers to disclose (and ultimately justify) costs of R&D, production and marketing.
read more


Related Posts

What you need to know on Wall Street right now

Business & Finance : Business Insider: Money Game

Finance Insider is Business Insider's summary of the top stories of the past 24 hours. The EpiPen controversy shows no sign of slowing down. Here are the headlines: Mylan is launching the first EpiPen generic at a discount of more t...

Sarah Jessica Parker cuts ties with Mylan over EpiPen prices

Business & Finance : Mashable: Business

Mylan has lost the trust of thousands of consumers, and now it has lost Sarah Jessica Parker.  The Sex and the City star cut ties with Mylan on Thursday over the pharmaceutical company's price increases to the EpiPen. Since Mylan bo...

The maker of the EpiPen is tanking after it was called out for hiking the drug's price by over 500%

Business & Finance : Business Insider: Money Game

Mylan Pharmaceuticals, the company that makes the emergency allergy medication EpiPen, is under pressure. The drugmaker's stock is down 4% Tuesday. That's after Sens. Chuck Grassley of Iowa and Richard Blumenthal of Connecticut wrot...

Sarah Jessica Parker Ends Mylan Partnership Over EpiPen Price Hike

News : Huffington Post

Sarah Jessica Parker has ended her relationship with the controversial pharmaceutical company Mylan. In May, the actress joined forces with the makers of the EpiPen through a campaign called Anaphylaxis for Reel. At the time, Parker...

Mylan's EpiPen Price 'Cut' An Outdated Drug Industry PR Move

Business & Finance : Forbes: Business

Even paying patient EpiPen copayments isn't blunting Mylan Pharmaceuticals 400% price increase for the live-saving auto-injection treatment for allergy sufferers.


Copyright © 2016 Regator, LLC